Pharmaceutical Industry Information Portal


All posts by tag


AbbVie and Cerebras collaborate to accelerate artificial intelligence biopharmaceutical research

Cerebras Systems, the pioneer in high performance artificial intelligence (AI) computing, and AbbVie, a global biopharmaceutical company, announced a landmark achievement in AbbVie’s AI...

AbbVie revenues exceeded forecasts, but fell short of expectations

AbbVie reported on Friday first quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. AbbVie announced earnings per share of $3.16...

AbbVie ends collaboration with BioArctic on alpha-synuclein portfolio

BioArctic AB (publ) has announced that the company's partner AbbVie has decided to terminate its collaboration with BioArctic regarding the portfolio of alpha-synuclein antibodies,...

Abbvie to collaborate with Gedeon Richter in neuropsychiatric diseases

AbbVie and Gedeon Richter Plc. ('Richter') today announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for...

COVID-19 dual-antibody therapies prevent emergence of drug resistance

Administration of antibody therapies bypasses the body’s slower and sometimes less effective process of making its own antibodies.

Expert Articles